Scheme document published for the £660 million recommended cash acquisition by H.B. Fuller for Advanced Medical Solutions
July 2026
Advanced Medical Solutions Group plc (AMS) is an LSE AIM listed world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers.
AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label.
H.B. Fuller Company is an NYSE listed Company and one of the world’s largest manufacturers of adhesives, sealants and other specialty chemical products. Founded in 1887 and headquartered in St. Paul, Minnesota, the company develops high-performance bonding solutions used across a wide range of industries, including packaging, construction, hygiene, electronics, automotive, medical devices, aerospace and consumer goods.
The Company operates globally, serving customers in more than 100 countries through an extensive manufacturing, research and development, and distribution network.
On 25 June 2026, the boards of directors of H.B. Fuller and AMS announced they had reached agreement on the terms of a recommended cash acquisition of the entire issued and to be issued ordinary share capital of AMS by H.B. Fuller Medical Adhesive Technologies Inc., a wholly owned subsidiary of H.B. Fuller.
The Acquisition values the entire issued and to be issued ordinary share capital of AMS at approximately £660 million and implies an enterprise value of approximately £716 million.
Publication of Scheme document
The Perivan shareholder communications team was delighted to work with Addleshaw Goddard who acted as legal adviser on the production of the scheme and associated documents which were successfully produced and posted to qualifying shareholders on 20 July 2026.
For further information, click here.
Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies and are a market leader for the production of documentation relating to Mergers & Acquisitions.